methoxsalen
Approved
Dec 3, 1954
Methoxsalen — also called xanthotoxin, marketed under the trade names Oxsoralen, Deltasoralen, Meladinine — is a drug used to treat psoriasis, eczema, vitiligo, and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, allegedly clearing up the disease. The dosage comes in 10 mg tablets, which are taken in the amount of 30 mg 75 minutes before a PUVA (psoralen + UVA) light treatment. Chemically, methoxsalen belongs to a class of organic natural molecules known as furanocoumarins. They consist of coumarin annulated with furan. It can also be injected and used topically. The exact mechanism of action of methoxsalen with the epidermal melanocytes and keratinocytes is not known. The best known biochemical reaction of methoxsalen is with DNA. Methoxsalen, upon photoactivation, conjugates and forms covalent bonds with DNA which leads to the formation of both monofunctional (addition to a single strand of DNA) and bifunctional adducts (crosslinking of psoralen to both strands of DNA) Reactions with proteins have also been described. Methoxsalen acts as a photosensitizer. Administration of the drug and subsequent exposure to UVA can lead to cell injury. Orally administered methoxsalen reaches the skin via the blood and UVA penetrates well into the skin. If sufficient cell injury occurs in the skin, an inflammatory reaction occurs. The most obvious manifestation of this reaction is delayed erythema, which may not begin for several hours and peaks at 48–72 hours. The inflammation is followed, over several days to weeks, by repair which is manifested by increased melanization of the epidermis and thickening of the stratum corneum. The mechanisms of therapy are not known. In the treatment of vitiligo, it has been suggested that melanocytes in the hair follicle are stimulated to move up the follicle and to repopulate the epidermis. In the treatment of psoriasis, the mechanism is most often assumed to be DNA photodamage and resulting decrease in cell proliferation but other vascular, leukocyte, or cell regulatory mechanisms may also be playing some role. Psoriasis is a hyperproliferative disorder and other agents known to be therapeutic for psoriasis are known to inhibit DNA synthesis. The most commonly reported side effect of methoxsalen alone is nausea, which occurs with approximately 10% of all patients. This effect may be minimized or avoided by instructing the patient to take methoxsalen with milk or food, or to divide the dose into two portions, taken approximately one-half hour apart. Other effects include nervousness, insomnia, and psychological depression. — NCATS
Clinical trial activity
27 trials · 35 clinical orgs · 9 marketing orgs
Earliest trial started Feb 1, 1996 (NCT00004359)
Timeline
1950s
- Dec 3, 1954
Earliest FDA Approval
- Dec 3, 1954
Bausch Health Companies — NDA Secondary Org
1980s
- Oct 30, 1986
Dow Pharmaceutical Sciences — NDA Secondary Org
- Oct 30, 1986
Bausch Health Companies — Marketing Organization
1990s
- Jan 1, 1996
Earliest Phase 2 Sponsor(trial)
- Feb 25, 1999
Mallinckrodt — NDA Secondary Org
- Feb 25, 1999
International Minerals and Chemical Corporation — NDA Secondary Org
2010s
- Jun 5, 2014
Strides Pharma Science — Marketing Organization
- Jun 9, 2015
Actavis — Marketing Organization
- Jun 9, 2015
Allergan PLC (2015) — Marketing Organization
Indications
Approved for
Studied for
- Arthritis, Rheumatoid · Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Colitis · Phase 2
- Crohn Disease · Phase 2
- Dermatitis, Atopic · Phase 3
- Epidermolysis Bullosa Acquisita · Phase 2
- Graft vs Host Disease · Phase 3
- Hematologic Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 3
- Lymphoma, T-Cell · Phase 4
- Lymphoma, T-Cell, Cutaneous · Phase 4
- Mycosis Fungoides · Phase 4
- Pancreatic Neoplasms · Phase 2
- Psoriasis · Phase 3
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 2
- Scleroderma, Diffuse · Phase 2
- Sezary Syndrome · Phase 2
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Approval history
- approvedPriority reviewDec 3, 1954
Chemistry & pharmacology
SMILES
COC1=C2OC(=O)C=CC2=CC3=C1OC=C3- Mol. weight
- 216.1895 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMethoxsalen ↗
- NCATSU4VJ29L7BQ ↗
- ChEMBLCHEMBL416 ↗
- ChEMBLCHEMBL24171 ↗
Also known as
- 4-methoxy-7h-furo(3,2-g)(1)benzopyran-7-one
- 5-methoxy-6,7-furanocoumarin
- 5 methoxypsoralen
- 5 methoxypsoralen
- 5-methoxypsoralen
- 5-methoxypsoralen
- 5-methoxypsoralen
- 5-methoxypsoralen
- 5-methoxypsoralen
- 6-hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone
- 6-hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone
- 8-methoxy-2',3',6,7-furocoumarin
- 8-methoxy-2',3',6,7-furocoumarin
- 8-methoxy-4',5':6,7-furocoumarin
- 8-methoxy-4',5':6,7-furocoumarin
- 8-methoxy-[furano-3'.2':6.7-coumarin]
- 8-methoxy-[furano-3'.2':6.7-coumarin]
- 8-methoxyfuranocoumarin
- 8-methoxyfuranocoumarin
- 8-methoxypsoralen
- 8-methoxypsoralen
- 8-methoxypsoralen
- 8-methoxypsoralen
- 8-methoxypsoralen
- 8-methoxypsoralene
- 8-mop
- 8-mop
- 8-mop
- 8-mop
- 8-mop
- 8-mop
- 8-mop
- 8-mp
- 8-mp
- 9-methoxy-7h-furo[3,2-g][1]benzopyran-7-one
- 9-methoxy-7h-furo[3,2-g][1]benzopyran-7-one
- ammoidin
- ammoidin
- bergaptan
- bergapten
- bergapten
- bergapten
- bergapten
- bergapten
- bergapten
- bergapten
- bergaptene
- cis,trans-xanthoxin
- deltapsoralen
- deltasoralen
- deltasoralen
- heraclin
- meladinin
- meladinine
- meladinine
- meladinine
- meladinine
- meladoxen
- meloxine
- meloxine
- meloxine
- methosaxalen
- methoxalen
- methoxalen
- methoxsalen
- methoxsalen
- methoxsalen
- methoxsalen
- methoxsalen
- methoxsalen
- methoxsalen
- methoxsalen
- methoxsalen
- methoxsalene
- méthoxsalène
- méthoxsalène
- methoxypsoralen
- methoxypsoralen
- o-methylxanthotoxol
- o-methylxanthotoxol
- oxsoralen
- oxsoralen
- oxsoralen
- oxsoralen
- oxsoralen-ultra
- oxsoralen-ultra
- puvasoralen-8
- trans,trans-5-(1',2'-epoxy-4'-hydroxy-2',6',6'- trimethyl-1'-cyclohexyl)-3-methylpentadienal
- trans,trans-xanthoxin
- ultra mop
- ultra mop
- uvadex
- uvadex
- xanthotoxin
- xanthotoxin
- xanthotoxin
- xanthotoxin
- xanthotoxine
- xanthotoxine
- xanthotoxine
- xanthoxin
- xanthoxin
- xanthoxin
- xanthoxin, (1r-(1alpha(2e,4e),4beta,6alpha))-isomer
- xanthoxin, (1s-(1alpha(2e,4e),4alpha,6alpha))-isomer
- xanthoxin, (1s-(1alpha(2z,4e),4alpha,6alpha))-isomer
- zanthotoxin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06646016 | Phase 2 | Jan 31, 2025 | Mallinckrodt |
| NCT04986605 | Phase 2 | Mar 31, 2022 | Mallinckrodt, University of Western Ontario |
| NCT05680558 | Phase 2 | May 8, 2021 | Columbia University, Mallinckrodt |
| NCT03778996 | Phase 2 | May 31, 2019 | Joseph Ahmed Foundation (JAF), Sarcoma Oncology Research Center, LLC, Tyme, Inc |
| NCT03563040 | Phase 2 | Dec 1, 2018 | European Organisation for Research and Treatment of Cancer, Karl Landsteiner Private University of Health Sciences, Mallinckrodt, Medical University of Vienna |
| NCT03605940 | Phase 2 | Oct 1, 2018 | University of Lorraine |
| NCT03512756 | Phase 2 | Mar 27, 2018 | Tyme, Inc |
| NCT02562612 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | Tyme, Inc |
| NCT02524847 | Phase 3 | Sep 1, 2015 | Mallinckrodt, Vanderbilt University |
| NCT02322190 | Phase 2 | Dec 4, 2014 | National Cancer Institute (NCI) |
| NCT01686594 | Phase 3 | Feb 1, 2013 | Medical University of Graz |
| NCT01380535 | Phase 1 | Nov 1, 2011 | Mallinckrodt, Parexel |
| NCT00930566 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2009 | Etablissement Français du Sang, University of Lyon |
| NCT00639717 | Phase 2 | Mar 1, 2009 | Amgen, Mallinckrodt, University of Michigan |
| NCT00811005 | Phase 3 | Oct 1, 2008 | University of Vienna |
| NCT00533195 | Phase 3 | Oct 1, 2007 | University of Vienna |
| NCT00282503 | Phase 3 | Jan 1, 2006 | Mallinckrodt, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT00221026 | Phase 2 | Dec 1, 2004 | ICON, Mallinckrodt |
| NCT00221039 | Phase 4 | Sep 1, 2004 | Boston University, Case Western Reserve University, Mallinckrodt, Rush University, University of Minnesota, University of Pittsburgh, University of Texas at Houston, Vanderbilt University |
| NCT00221000 | Phase 2 | Aug 1, 2003 | Mallinckrodt, Rebecca MacDonald Centre for Arthritis |
Organizations
Research & Development (35)
Marketing (10)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Actavis | For profit | MKTG | Jun 9, 2015 |
| Allergan PLC (2015) | For profit | MKTG | Jun 9, 2015 |
| Ani Pharmaceuticals | For profit | MKTG | — |
| Bausch Health Companies | For profit | NDA2 | Dec 3, 1954 |
| Bausch Health Companies | For profit | MKTG | Oct 30, 1986 |
| Dow Pharmaceutical Sciences | For profit | NDA2 | Oct 30, 1986 |
| International Minerals and Chemical Corporation | For profit | NDA2 | Feb 25, 1999 |
| Mallinckrodt | For profit | NDA2 | Feb 25, 1999 |
| Paul B Elder Company | For profit | NDA | — |
| Strides Pharma Science | For profit | MKTG | Jun 5, 2014 |